

Haematologica
HAEMATOL/2019/223966
Version 3

Eltrombopag for the treatment of inherited thrombocytopenias: a phase
2 clinical trial

Carlo Zaninetti, Paolo Gresele, Antonella Bertomoro, Catherine Klersy,
Erica De Candia, Dino Veneri, Serena Barozzi, Tiziana Fierro, Maria
Adele Alberelli, Valeria Musella, Patrizia Noris, Fabrizio Fabris, Carlo L
Balduini, and Alessandro Pecci

Disclosures: This study was supported in part by grants from the IRCCS Policlinico San Matteo Foundation (to A.P.) and the Telethon Foundation (GGP17106 to A.P. and GGP10155 to P.G.). Novartis made eltrombopag available for the study and partially supported the clinical and laboratory analyses required by the trial. All the authors declare no conflicts of interest or competing financial interests.

Contributions: CZ and AP designed research, collected clinical and laboratory data, analyzed and interpreted data, and wrote the manuscript. CLB designed research, analyzed and interpreted data, and wrote the manuscript. PG, AB, EDC, DV, SB, TF, MAA, PN, and FF collected clinical and laboratory data, analyzed and interpreted data. CK analyzed and interpreted data and performed statistical analysis. VM analyzed and interpreted data and coordinated data management. All authors had access to primary clinical trial data. All the authors critically revised the manuscript and accepted the final version.